Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21-40 months of age

Marta Ciofi Degli Atti, Alessandra Anemona, Alberto Eugenio Tozzi, Paola Stefanelli, Anna Giammanco, Stefania Salmaso

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The reactogenicity of a three-dose catch-up acellular pertussis (aP) immunization of children at 21-40 months of age was evaluated. Vaccination was well-tolerated: fever ≥38°C was reported after 5% of administered doses and local reactions after 14-15%. The onset of adverse events was not associated with age at vaccination, interval between doses or previous presence of antibodies against pertussis, whereas injection in sites other than the buttock and presence of the same symptom after a previous dose were associated with higher reactogenicity. Because of the good safety profile of primary aP immunization in children > 1 year of age, catch-up vaccination campaigns could be considered in areas where pertussis whole-cell vaccination uptake has been low and where the number of susceptible children should be reduced to control pertussis circulation.

Original languageEnglish
Pages (from-to)2030-2035
Number of pages6
JournalVaccine
Volume17
Issue number15-16
DOIs
Publication statusPublished - Apr 9 1999

Fingerprint

Acellular Vaccines
Pertussis Vaccine
Whooping Cough
vaccination
vaccines
dosage
Vaccination
immunization
buttocks
Immunization
injection site
administered dose
Immunization Programs
Buttocks
signs and symptoms (animals and humans)
fever
uptake mechanisms
Fever
antibodies
Safety

Keywords

  • Acellular pertussis vaccines
  • Catch-up
  • Safety

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21-40 months of age. / Ciofi Degli Atti, Marta; Anemona, Alessandra; Tozzi, Alberto Eugenio; Stefanelli, Paola; Giammanco, Anna; Salmaso, Stefania.

In: Vaccine, Vol. 17, No. 15-16, 09.04.1999, p. 2030-2035.

Research output: Contribution to journalArticle

Ciofi Degli Atti, Marta ; Anemona, Alessandra ; Tozzi, Alberto Eugenio ; Stefanelli, Paola ; Giammanco, Anna ; Salmaso, Stefania. / Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21-40 months of age. In: Vaccine. 1999 ; Vol. 17, No. 15-16. pp. 2030-2035.
@article{bd8be210a1404b88999e23d8235f42c1,
title = "Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21-40 months of age",
abstract = "The reactogenicity of a three-dose catch-up acellular pertussis (aP) immunization of children at 21-40 months of age was evaluated. Vaccination was well-tolerated: fever ≥38°C was reported after 5{\%} of administered doses and local reactions after 14-15{\%}. The onset of adverse events was not associated with age at vaccination, interval between doses or previous presence of antibodies against pertussis, whereas injection in sites other than the buttock and presence of the same symptom after a previous dose were associated with higher reactogenicity. Because of the good safety profile of primary aP immunization in children > 1 year of age, catch-up vaccination campaigns could be considered in areas where pertussis whole-cell vaccination uptake has been low and where the number of susceptible children should be reduced to control pertussis circulation.",
keywords = "Acellular pertussis vaccines, Catch-up, Safety",
author = "{Ciofi Degli Atti}, Marta and Alessandra Anemona and Tozzi, {Alberto Eugenio} and Paola Stefanelli and Anna Giammanco and Stefania Salmaso",
year = "1999",
month = "4",
day = "9",
doi = "10.1016/S0264-410X(98)00405-8",
language = "English",
volume = "17",
pages = "2030--2035",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "15-16",

}

TY - JOUR

T1 - Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21-40 months of age

AU - Ciofi Degli Atti, Marta

AU - Anemona, Alessandra

AU - Tozzi, Alberto Eugenio

AU - Stefanelli, Paola

AU - Giammanco, Anna

AU - Salmaso, Stefania

PY - 1999/4/9

Y1 - 1999/4/9

N2 - The reactogenicity of a three-dose catch-up acellular pertussis (aP) immunization of children at 21-40 months of age was evaluated. Vaccination was well-tolerated: fever ≥38°C was reported after 5% of administered doses and local reactions after 14-15%. The onset of adverse events was not associated with age at vaccination, interval between doses or previous presence of antibodies against pertussis, whereas injection in sites other than the buttock and presence of the same symptom after a previous dose were associated with higher reactogenicity. Because of the good safety profile of primary aP immunization in children > 1 year of age, catch-up vaccination campaigns could be considered in areas where pertussis whole-cell vaccination uptake has been low and where the number of susceptible children should be reduced to control pertussis circulation.

AB - The reactogenicity of a three-dose catch-up acellular pertussis (aP) immunization of children at 21-40 months of age was evaluated. Vaccination was well-tolerated: fever ≥38°C was reported after 5% of administered doses and local reactions after 14-15%. The onset of adverse events was not associated with age at vaccination, interval between doses or previous presence of antibodies against pertussis, whereas injection in sites other than the buttock and presence of the same symptom after a previous dose were associated with higher reactogenicity. Because of the good safety profile of primary aP immunization in children > 1 year of age, catch-up vaccination campaigns could be considered in areas where pertussis whole-cell vaccination uptake has been low and where the number of susceptible children should be reduced to control pertussis circulation.

KW - Acellular pertussis vaccines

KW - Catch-up

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=0344267740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344267740&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(98)00405-8

DO - 10.1016/S0264-410X(98)00405-8

M3 - Article

C2 - 10217603

AN - SCOPUS:0344267740

VL - 17

SP - 2030

EP - 2035

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 15-16

ER -